Investigational drug · Phase 2
HRS-5041
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "HRS-5041"
First trial start
2024
Sep 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-5041", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-5041" as an intervention, largest first.
- Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05942001 · 100 participants (planned) · Start Aug 3, 2023 · Primary completion Sep 2026
Drug: HRS-5041; Docetaxel injection and 3 more · For: Advanced Prostate Cancer
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07407283 · 100 participants (planned) · Start Apr 8, 2026 · Primary completion Nov 2027
Drug: SHR-4394; Rezvilutamide and 2 more · For: Prostate Cancer
Sites: Chengdu, China; Tianjin, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06568094 · 100 participants (planned) · Start Sep 25, 2024 · Primary completion Dec 2026
Drug: HRS-5041 tablets; Abiraterone Acetate tablets(II) and 6 more · For: Prostate Cancer
Sites: Harbin, China; Shanghai, China
- Study of HRS-2189 Combined HRS-5041 in Prostate CancerNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06738745 · 90 participants (planned) · Start Dec 31, 2024 · Primary completion Jan 31, 2027
Drug: HRS-2189; HRS-5041 · For: Prostate Cancer Metastatic Disease
Sites: Shanghai, China
Hansoh BioMedical R&D CompanyIndustry
NCT07115446 · 63 participants (planned) · Start Aug 19, 2025 · Primary completion Dec 2027
Drug: HS-20093; HRS-5041 · For: Advanced Prostate Cancer
Sites: Shanghai, China
- A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate CancerActive, not recruiting
Atridia Pty Ltd.Industry
NCT06830850 · 25 participants (planned) · Start Jun 15, 2025 · Primary completion Dec 30, 2026
Drug: HRS-5041 Single dose of HRS-5041 orally administered · For: Metastatic Castration Resistant Prostate Cancer
Sites: Sydney, Australia; Adelaide, Australia; Brisbane, Australia · 11 sites in all
Atridia Pty Ltd.Industry
NCT06559007 · 24 participants · Start Sep 25, 2024 · Primary completion Jan 6, 2025
Drug: HRS-5041 dose level 1; HRS-5041 dose level 2 · For: Prostate Cancer
Sites: Melbourne, Australia
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07014488 · 16 participants · Start Jun 20, 2025 · Primary completion Aug 1, 2025
Drug: HRS-5041 Tablets; Rifampicin Capsule · For: Prostate Cancer
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.